Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia

AIMS: This population pharmacokinetic analysis was conducted to describe quantitatively the regional differences and sources of interpatient variability on the apparent oral clearance of alisertib. METHODS: A population pharmacokinetic analysis was performed on data from 671 cancer patients in Weste...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Clin Pharmacol
Asıl Yazarlar: Zhou, Xiaofei, Mould, Diane R., Takubo, Takatoshi, Sheldon‐Waniga, Emily, Huebner, Dirk, Milton, Ashley, Venkatakrishnan, Karthik
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2017
Konular:
Clinical Trials
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5736852/
https://ncbi.nlm.nih.gov/pubmed/28891222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13430
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller